Fig. 2: Distributions of placebo ketamine, active ketamine, and active lamotrigine + active ketamine connectivity from significant clusters. | Molecular Psychiatry

Fig. 2: Distributions of placebo ketamine, active ketamine, and active lamotrigine + active ketamine connectivity from significant clusters.

From: Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia

Fig. 2

Boxplots showing distributions of participant-level connectivity means for each drug condition, for each significant cluster obtained from the [active ketamine – saline] > [placebo ketamine – saline] contrast (voxel-z > 3.29, corrected cluster-p < 0.05); anatomical location details for clusters 1 through 7 are found in Supplementary Table S4. PL placebo ketamine, Ket active ketamine, Lam active lamotrigine. Asterisks reflect significance levels from follow-up two-sided pairwise tests (based on the corresponding repeated measures ANOVA for that cluster). Uncorrected ***p < 0.001.

Back to article page